Physician profile
Ann Shum
NPI 1023662640
$34,875.10
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $862 · 2023: $9,592 · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $9,707 · Food and Beverage: $3,875 · Consulting Fee: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,888.00 |
| Travel and Lodging | $9,706.52 |
| Food and Beverage | $3,874.78 |
| Consulting Fee | $1,237.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14,074.33 | 2023-2024 | Omvoh |
| Janssen Biotech, INC. | $12,785.97 | 2021-2025 | Tremfya, Stelara |
| Eli Lilly and Company | $4,792.46 | 2023 | |
| Pfizer INC. | $1,231.63 | 2023-2024 | |
| Abbvie INC. | $584.36 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.03 | 2021-2022 | |
| Madrigal Pharmaceuticals | $306.78 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $276.87 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $125.94 | 2025 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2021 | |
| Janssen Scientific Affairs, LLC | $110.98 | 2022 | |
| Novo Nordisk INC | $21.26 | 2024 | Wegovy |
| Celgene Corporation | $16.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Shum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.